10-Q: Tenon Medical Reports Q2 2026 Results, Faces Nasdaq Scrutiny

Tenon Medical, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing revenue growth driven by its SI joint fusion systems, but also highlighting significant operating losses and ongoing concerns about its ability to continue as a going concern.

Summary

• Tenon Medical, Inc. reported its financial results for the second quarter and first half of 2026, showing significant revenue increases compared to the prior year.
• The company's revenue grew by 127% to $1,279,000 for the three months ended June 30, 2026, and by 106% to $2,658,000 for the six months ended June 30, 2026.
• Despite revenue growth, the company incurred substantial net losses, with a loss of $4,050,000 for the three months and $7,526,000 for the six months ended June 30, 2026.
• The accumulated deficit stands at $88.8 million as of June 30, 2026.
• The company received notices from Nasdaq regarding minimum bid price and stockholders' equity requirements, though it believes a recent reverse stock split will help regain compliance.
• A public offering on July 1, 2026, raised approximately $3.6 million in net proceeds, intended for debt repayment, commercial expansion, R&D, and working capital.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, citing insufficient funds to meet obligations for the next 12 months.
• The company is actively seeking additional capital through various financing methods.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's ongoing net losses, substantial accumulated deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite recent revenue growth and a capital raise.

Positives

• Significant year-over-year revenue growth for both the three-month (127%) and six-month (106%) periods, reaching $1.28 million and $2.66 million, respectively.
• Revenue growth is attributed to increased surgical procedures and the inclusion of revenue from the SImmetry+ System.
• Gross profit margin improved significantly to 64% for the three months and 66% for the six months ended June 30, 2026, up from 43% and 44% in the prior year periods.
• Successful completion of a public offering on July 1, 2026, raising approximately $3.6 million in net proceeds.
• A 1-for-35 reverse stock split was effected on August 10, 2026, which is expected to help regain compliance with Nasdaq's minimum bid price rule.
• The company regained compliance with Nasdaq's minimum stockholders' equity requirement as of July 10, 2026.

Negatives

• Substantial net losses continue, with a $4.05 million loss in Q2 2026 and a $7.53 million loss in the first half of 2026.
• The company has an accumulated deficit of $88.8 million as of June 30, 2026.
• Management has stated there is substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• Operating expenses increased by 34% for the three months and 18% for the six months ended June 30, 2026, outpacing revenue growth in absolute terms.
• The company received notices from Nasdaq for not meeting the minimum bid price and stockholders' equity requirements, indicating potential delisting risks.
• The company's cash and cash equivalents decreased to $1.7 million as of June 30, 2026, from $3.76 million at the end of 2025.

Risks

• The company has substantial doubt about its ability to continue as a going concern.
• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting.
• The company may not be able to raise sufficient additional capital on acceptable terms, which could force it to delay or suspend operations.
• Increased operating expenses, particularly in sales and marketing and R&D, are expected to continue.
• The company's revenue is derived from a limited number of clinicians, creating a concentration risk.
• Competition in the medical device industry is intense, and the company's ability to compete and succeed is not guaranteed.
• The company's intellectual property protection and brand development are critical for its success.

Future Outlook

The company expects operating expenses to increase in absolute dollars as it continues to invest in business growth, product development, and commercialization efforts. Management plans to raise additional capital through equity or debt offerings to fund operations, as current cash and proceeds from a recent offering are not expected to be sufficient for the next 12 months. The company anticipates continued revenue growth and aims to improve its financial position.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date.
• Management believes the reverse stock split will allow the company to regain compliance with the Nasdaq Bid Price Rule.
• Management believes the company satisfies the minimum stockholders equity requirement as of July 10, 2026, following the public offering.

Industry Context

StockSavvy.ai notes that Tenon Medical operates in the competitive medical device sector, specifically focusing on sacro-pelvic disorders. The company's revenue growth is a positive sign, but the persistent net losses and going concern uncertainty are significant headwinds common to many early-stage medical device companies striving for market penetration and profitability.

Comparison to Industry Standards

• The company's gross margin improvement (64% vs. 43% in Q2 2026 vs. Q2 2025) is a strong positive trend, outperforming many early-stage medical device companies that often struggle with initial gross margins due to manufacturing scale and product costs.
• However, the significant increase in operating expenses (34% in Q2 2026 vs. Q2 2025) as a percentage of revenue (326% vs. 550%) indicates a substantial investment phase, which is typical but requires careful management to achieve profitability.
• The company's net loss per share of $(12.35) for Q2 2026, while substantial, is an improvement from $(12.76) in Q2 2025, suggesting a slight reduction in per-share loss despite the overall increase in net loss.
• The ongoing Nasdaq compliance issues (bid price and equity) are common challenges for companies in this sector that are not yet consistently profitable or have experienced significant stock price volatility.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, ongoing Nasdaq compliance risks, and substantial doubt about the company's going concern status.
• Creditors: The company is seeking to partially repay outstanding convertible notes with proceeds from the recent offering.
• Employees: Continued investment in R&D and sales/marketing may lead to hiring, but financial instability poses job security risks.
• Suppliers: Increased production capacity and inventory may lead to higher demand for raw materials and manufacturing services.

Next Steps

• Regain compliance with Nasdaq's minimum bid price rule, expected around August 21, 2026, following the reverse stock split.
• Continue to seek additional capital through equity offerings, debt financings, or collaborations.
• Use proceeds from the July 2026 offering for partial repayment of convertible notes, expansion of commercial footprint, clinician training, hiring sales representatives, expanding distribution, clinical research, R&D, inventory/instrumentation capacity increases, marketing, working capital, and general corporate purposes.
• Monitor compliance with Nasdaq's stockholders equity rule and evidence compliance in the Q3 2026 Form 10-Q filing.

Key Dates

Recommendation

The company exhibits significant financial distress with substantial net losses, an increasing accumulated deficit, and explicit statements of doubt regarding its ability to continue as a going concern. While revenue growth is positive, it is not yet translating into profitability, and the company faces ongoing Nasdaq compliance challenges. The need for continuous capital raises, which dilute existing shareholders, coupled with the inherent risks of early-stage medical device companies, makes the risk profile unfavorable for investment at this time.

Keywords

SI Joint Fusion, Medical Device, Catamaran System, SImmetry+ System, Nasdaq Compliance, Capital Raise, Operating Loss, Going Concern